drugset / Trial / NCT06665646
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.
Timeline
- Start
- 2025-09-14
- Primary completion
- 2026-07-27
- Completion
- 2027-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD40.HIVRI.Env | Vaccine | 1 mg | Subcutaneous |
| Background | Hiltonol | Other / unclassified | — | Subcutaneous |